We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
These biomarkers data begin to illuminate bortezomib's mechanism of action in lymphoma.
2
Results: Thirty-one per cent of patients received bortezomib beyond first relapse.
3
However, apoptotic response to bortezomib was not affected by the deletion of p53.
4
Recently, it has been shown that bortezomib treatment enhances OB function.
5
The safety profile was consistent with that reported for single-agent bortezomib and romidepsin.
1
The inhibitors tested included several peptideboronates, some of which proved to be the most potent peptide-based inhibitors of beta-amyloid production reported so far.
Usage of ps-341 in English
1
TUNEL staining indicated that PS-341 treatment sensitizes Tax tumors to DNA fragmentation.
PSI suppressed the growth of AML cell lines more effectively than PS-341.
4
Both preclinical and clinical studies of novel agents including PS-341 and IMiDs are highlighted.
5
The tumor tissues treated with PS-341 show no consistent inhibition of NFkappaB activation in vivo.
6
Annexin V staining indicated that PS-341 response in vivo correlated with sensitivity to apoptosis induced by gamma irradiation.
7
However, the effect of PS-341 on the growth of tumors in Tax transgenic mice revealed heterogeneity in drug responsiveness.
8
Radiosensitization by PS-341 was reduced in fish with impaired p53 expression or function but not associated with enhanced expression of select p53 target genes.